Literature DB >> 14514981

Epoetin alfa and intravenous iron sucrose to treat severe anemia in a patient with chronic radiation enteropathy: a case report.

Sophie Séronie-Vivien1, Loïc Mourey, Moustapha Tohfe, Roland Bugat.   

Abstract

We report the case of a patient with a severe chronic radiation enteropathy. She had been dependent on red cell transfusions for many years. On admission, she displayed anemia (8.6 g/dL) resulting from both inadequate EPO production and a functional iron deficiency. A 3-wk IV iron sucrose treatment (200 mg once weekly) resulted in an increased reticulocyte count, but did not raise the hemoglobin (Hb) level. The adjunction of epoetin alpha (10,000 IU three times a week) made it possible to reach the normal range (12.9 g/dL) after a 17-wk treatment. As the anti-anemic treatment discontinued, the Hb level decreased to 11.1 g/dL within 2 wk. Giving EPO again (10,000 IU twice a week) failed to maintain the Hb level, which dropped under basal values (7.8 g/dL). In contrast, a second combination EPO/iron sucrose did restore a normal Hb level and maintained it. This case report supports the combination of EPO and IV iron supplementation in patients with anemia of chronic disease and either an impaired iron absorption or intolerance to oral iron.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514981     DOI: 10.1385/MO:20:3:301

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

1.  Intravenous versus oral iron supplementation for preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin.

Authors:  R G Rohling; A P Zimmermann; C Breymann
Journal:  J Hematother Stem Cell Res       Date:  2000-08

2.  Recombinant human erythropoietin as adjuvant treatment for autologous blood donation in elective surgery with large blood needs (> or = 5 units): a randomized study.

Authors:  C de Pree; B Mermillod; P Hoffmeyer; P Beris
Journal:  Transfusion       Date:  1997-07       Impact factor: 3.157

3.  Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial.

Authors:  C Gasché; C Dejaco; T Waldhoer; W Tillinger; W Reinisch; G F Fueger; A Gangl; H Lochs
Journal:  Ann Intern Med       Date:  1997-05-15       Impact factor: 25.391

Review 4.  Role of iron in optimizing responses of anemic cancer patients to erythropoietin.

Authors:  J Glaspy; I Cavill
Journal:  Oncology (Williston Park)       Date:  1999-04       Impact factor: 2.990

5.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Authors:  T J Littlewood; E Bajetta; J W Nortier; E Vercammen; B Rapoport
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

6.  Erythropoietin treatment of anemia associated with multiple myeloma.

Authors:  H Ludwig; E Fritz; H Kotzmann; P Höcker; H Gisslinger; U Barnas
Journal:  N Engl J Med       Date:  1990-06-14       Impact factor: 91.245

7.  [Chronic radiation enteritis. II. General consequences and prognostic factors].

Authors:  J Cosnes; J P Gendre; Y Le Quintrec
Journal:  Gastroenterol Clin Biol       Date:  1983 Aug-Sep

Review 8.  Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.

Authors:  J W Adamson; H Ludwig
Journal:  Oncology       Date:  1999       Impact factor: 2.935

9.  Erythropoietin increases hemoglobin in cancer patients during radiation therapy.

Authors:  R S Lavey; W H Dempsey
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-12-01       Impact factor: 7.038

10.  Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy.

Authors:  J A Glaspy; J S Jadeja; G Justice; J Kessler; D Richards; L Schwartzberg; N S Tchekmedyian; S Armstrong; J O'Byrne; G Rossi; A B Colowick
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.